Q4 2024 SeaStar Medical Holding Corp Earnings Call Transcript
Key Points
- SeaStar Medical Holding Corp (ICU) launched Coelimmune, witnessing significant positive patient outcomes, including life-saving interventions.
- The company received its first product approval for QELimmune and advanced its neutralized AKI clinical development program.
- SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its contributions to pediatric AKI treatment.
- The company secured key patents in the United States and Canada, strengthening its proprietary technology.
- SeaStar Medical raised approximately $25 million, improved its balance sheet, and reduced debt, positioning itself for future growth.
- The adoption process for Coelimmune is lengthy and unpredictable, involving Investigational Review Boards (IRBs) and patient registries.
- Sales of Coelimmune are expected to be 'lumpy' due to the time required for hospitals to adopt the therapy.
- The company is not providing specific revenue guidance due to uncertainties inherent in launching a new product.
- SeaStar Medical faced challenges with a national shortage of citrate, impacting the enrollment pace of its Neutralized AKI trial.
- Operating expenses increased by approximately $3.6 million in 2024, primarily due to commercial launch activities and clinical trial enrollments.
Good afternoon and thank you for standing by. My name is Calvin and I will be your conference operator today. At this time, I would like to welcome everyone to the SeaStar Medical year-end 2024 financial results conference call.
(Operator Instructions) Thank you. I would now like to turn the call over to Jackie Cosman. Please go ahead.
Thank you, Calvin. Good afternoon, and thank you for joining the SeaStar Medical year-end 2024 financial results conference call. I'm Jackie Cosman with Wheelhouse Life Science Advisors. Joining me from SeaStar Medical today are Eric Schlorf, Chief Executive Officer, David Green, Chief Financial Officer, Dr. Kevin Chung, Chief Medical Officer, and Tim Verocek, Senior Vice President of Commercial and Business Operations.
I would like to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
